Human Metabolome Technologies, Inc. (JP:6090)
:6090
Want to see JP:6090 full AI Analyst Report?
6090 Stock Chart & Stats
¥715.00
¥1.00(0.16%)
At close: 4:00 PM EST
¥715.00
¥1.00(0.16%)
Day’s Range― - ―
52-Week Range¥581.00 - ¥848.00
Previous CloseN/A
Volume5.70K
Average Volume (3M)10.25K
Market Cap
¥3.65B
Enterprise Value¥2.28B
Total Cash (Recent Filing)¥1.59B
Total Debt (Recent Filing)¥110.47M
Price to Earnings (P/E)29.1
Beta0.24
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.35%
Share Statistics
EPS (TTM)43.61
Shares Outstanding5,919,797
10 Day Avg. Volume8,100
30 Day Avg. Volume10,250
Financial Highlights & Ratios
PEG Ratio2.95
Price to Book (P/B)2.36
Price to Sales (P/S)3.09
P/FCF Ratio19.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a strong equity ratio provide durable financial flexibility, enabling the company to fund R&D, weather cyclical slowdowns, and pursue selective partnerships or investments without stressing cash flow or requiring dilutive financing over the next several quarters.
High And Sustainable MarginsElevated gross and net margins reflect a high-value, service-oriented business model with pricing power and scalable analytics workflows. Such margin structure supports reinvestment in technology and profitability resilience even if top-line growth slows over the medium term.
Proprietary Metabolomics Platform And Diversified ClientsProprietary analytical technology and exposure to multiple end markets create enduring competitive advantages: differentiation versus commoditized labs, recurring project demand from R&D customers, and reduced dependency on any single vertical over a multi-quarter horizon.
Bears Say
Negative Revenue TrendMaterial negative revenue growth indicates customer demand or pricing pressure and undermines scalability. If top-line contraction persists, it can erode operating leverage, constrain reinvestment in product development, and limit long‑term market share expansion.
Cash Flow VolatilityIntermittent negative FCF growth signals volatility in cash generation that can restrict capital allocation choices. Over several quarters, this may limit consistent R&D spend, delay capacity expansion, and raise reliance on balance sheet buffers despite current low leverage.
Small Operational ScaleA small employee base constrains throughput and geographic expansion and increases execution risk versus larger competitors. Scaling sales, accelerating new service rollout, or absorbing large institutional contracts may require significant hiring and investment, pressuring margins near term.
Human Metabolome Technologies, Inc. News
6090 FAQ
What was Human Metabolome Technologies, Inc.’s price range in the past 12 months?
Human Metabolome Technologies, Inc. lowest stock price was ¥581.00 and its highest was ¥848.00 in the past 12 months.
What is Human Metabolome Technologies, Inc.’s market cap?
Human Metabolome Technologies, Inc.’s market cap is ¥3.65B.
When is Human Metabolome Technologies, Inc.’s upcoming earnings report date?
Human Metabolome Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were Human Metabolome Technologies, Inc.’s earnings last quarter?
Human Metabolome Technologies, Inc. released its earnings results on May 13, 2026. The company reported ¥21.61 earnings per share for the quarter, beating the consensus estimate of N/A by ¥21.61.
Is Human Metabolome Technologies, Inc. overvalued?
According to Wall Street analysts Human Metabolome Technologies, Inc.’s price is currently Overvalued.
Does Human Metabolome Technologies, Inc. pay dividends?
Human Metabolome Technologies, Inc. pays a Annually dividend of ¥18 which represents an annual dividend yield of 2.35%. See more information on Human Metabolome Technologies, Inc. dividends here
What is Human Metabolome Technologies, Inc.’s EPS estimate?
Human Metabolome Technologies, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Human Metabolome Technologies, Inc. have?
Human Metabolome Technologies, Inc. has 5,919,797 shares outstanding.
What happened to Human Metabolome Technologies, Inc.’s price movement after its last earnings report?
Human Metabolome Technologies, Inc. reported an EPS of ¥21.61 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.147%.
Which hedge fund is a major shareholder of Human Metabolome Technologies, Inc.?
Currently, no hedge funds are holding shares in JP:6090
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. is a biotechnology company based in Tsuruoka, Japan, established in 2003. It focuses on developing and providing metabolomics technologies and solutions for a range of applications, including drug discovery, disease diagnosis, and food production primarily within Japan. The company offers a comprehensive suite of metabolome analysis services, encompassing global profiling, targeted assays, flux analysis, and lipidomics. Additionally, it develops biomarkers, such as Phosphorylethanolamine, which is measured in blood plasma as a marker for major depressive disorder. HMT's solutions address diverse areas like cancer metabolism, infectious diseases, basic and clinical research, food and nutrition, and microbiome studies. The company also fosters collaborations, notably with the Institute for Advanced Biosciences and Keio University, to further advance metabolome analysis technology.
Technical Analysis
BML
―
Shin Nippon Biomedical Laboratories, Ltd.
―
Cosmo Bio Co., Ltd.
―
Kainos Laboratories, Inc.
―
Perseus Proteomics, Inc.
―